CPIT with n-IFN-β followed by triple therapy with PI with PR is more effective for the treatment of difficult-to-treat CHC patients with genotype 1b and high viral loads than CPIT with n-IFN-β followed by PR alone. This evidence concerns the gene IFNB1 and cryohydrocytosis.